The seroprevalence of Mycoplasma pneumoniae IgM and IgG antibodies in patients with ischemic stroke
Abstract
Background and Objectives: Association between Mycoplasma pneumoniae infection and increased risk for brain stroke has been well understood. Hence, the value of serologic tests for assessing causative relationship between this infection and brain stroke seems to be high. The present study aimed to determine serum level of anti-Mycoplasma pneumoniae antibodies in patients with brain stroke and to compare it with non-stroke patients.
Materials and Methods: This cross-sectional study was performed on 97 consecutive ischemic stroke patients and 97 sex and age-matched non-stroke patients. Quantitative enzyme-linked immunosorbent assay (ELISA) was established to measure the levels of anti-Mycoplasma pneumoniae IgG and IgM antibodies.
Results: Regarding the level of anti-Mycoplasma pneumoniae IgM, the titer of this marker was positive in 4.1% of patients with ischemic stroke, while none of the subjects in control group had positive titer for this antibody (OR = 1.043, 95%CI:1.001 – 1.087, p = 0.043). The rate of positivity for anti-Mycoplasma pneumoniae IgG in ischemic stroke patients was significantly higher than in the control group (28.5% versus 13.4%, p = 0.031). Odds ratio for exposure to M. pneumoniae was 2.24 times of the control subjects. The level of anti-Mycoplasma pneumoniae IgM was independent to both sex and age variables in patients group (p = 0.77). The level of anti-Mycoplasma pneumoniae IgG did not depend on subjects’ gender in control group, but was significantly higher in men compared with women in patients group.
Conclusion: A high level of anti-Mycoplasma pneumoniae IgM and IgG antibodies indicate a significant association of M. pneumoniae infection and history of this infection with increased risk for ischemic stroke.
Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Ba- nerjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Be- cher H, Hacke W: Recent infection as a risk factor for cerebrovascular ischaemia. Stroke 1995; 26:373-379.
Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S: Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998;26:719-734.
Ngeh J, Anand V, Gupta S: Chlamydia pneumonia and atherosclerosis – What we know and what we don’t. Clin Microbiol Infect 2002; 8:2-13.
Kalayoglu MV, Libby P, Byrne GI: Chlamydia pneu- moniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288:2724-2731.
Taylor-Robinson D: Infections due to species of My- coplasma and Ureaplasma: An update. Clin Infect Dis 1996; 23:671-684.
Taylor-Robinson D, Thomas BJ: Chlamydia pneumoni- ae in arteries: The facts, their interpretation, and future studies. J Clin Pathol 1998; 51:793-797.
Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae in- fection in adults. Am J Med 1975; 58:229-242.
Cassell GH, Cole BC. Mycoplasmas as agents of hu- man disease. N Engl J Med 1981; 304:80-89.
Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cas- es at the University of Helsinki and review. Clin Infect Dis 1993; 17:S52-S7.
Lind K, Zoffman H, Larsen SO, Jessen O. Mycoplasma pneumoniae infection associated with affection of cen- tral nervous system. Acta Med Scand 1979; 205:325-332.
Urquhart GED. Mycoplasma pneumoniae infection and neurological complications [letter]. Br Med J 1979;2:1512.
Hu CF, Wang CC, Chen SJ, Perng CL, Yang HY, Fan HC. Prognostic values of a combination of intervals between respiratory illness and onset of neurological symptoms and elevated serum IgM titers in Mycoplas- ma pneumoniae encephalopathy. J Microbiol Immunol Infect 2014;47:497-502.
Kong M, Jiang L, Hu J, Ye YZ. Clinical characteris- tics of Mycoplasma pneumoniae-associated ischemic stroke in children and a literature review. Zhongguo Dang Dai Er Ke Za Zhi 2012; 14:823-826.
NjeukuiTchoua J1, Noel S, Sellitti E, Vanderheyden JE, Blaze V. Acute disseminated encephalomyelitis associ- ated with Mycoplasma pneumoniae infection. Rev Med Brux 2008 ; 29:103-106.
Hsing J1, Welgampola M, Kiernan MC. Reversible my- eloradiculopathy due to Mycoplasma pneumoniae. J Clin Neurosci 2007; 14:61-64.
Greco F1, CastellanoChiodo D, Sorge A, Perrini S, Sorge G. Multiple arterial ischemic strokes in a child with moyamoya disease and Mycoplasma pneumoniae infection. Minerva Pediatr 2006; 58:63-68.
Tsiodras S1, Kelesidis I, Kelesidis T, Stamboulis E, Giamarellou H. Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect 2005;51:343-354.
Padovan CS, Pfister HW, Bense S, Fingerle V, Abele- Horn M. Detection of Mycoplasma pneumoniae DNA in cerebrospinal fluid of a patient with M. pneumoni- ae infection-"associated" stroke. Clin Infect Dis 2001;33:E119-21.
Chiang CH, Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, et al. Association between Mycoplasma pneu- moniae and increased risk of ischemic stroke: a nation- wide study. Stroke 2011; 42:2940-2943.
Levine DP, Lerner AM. The clinical spectrum of My- coplasma pneumoniae infections. Med Clin North Am 1978; 62:961–978
Ngeh J, Goodbourn C. Chlamydia pneumoniae, Myco- plasma pneumoniae, and Legionella pneumophila in el- derly patients with stroke (C-PEPS, M-PEPS, L-PEPS): a case-control study on the infectious burden of atypi-cal respiratory pathogens in elderly patients with acute cerebrovascular disease. Stroke 2005; 36:259-265.
Padovan CS, Pfister HW, Bense S, Fingerle V, Abele- Horn M. Detection of Mycoplasma pneumoniae DNA in cerebrospinal fluid of a patient with M. pneumoni- ae infection-"associated" stroke. Clin Infect Dis 2001;33:E119-121.
Ngeh J1, Gupta S, Goodbourn C, McElligott G. Myco- plasma pneumoniae in elderly patients with stroke.a case-control study on the seroprevalence of M. pneu- moniae in elderly patients with acute cerebrovascular disease - the M-PEPS Study. Cerebrovasc Dis 2004;17:314-319.
Kong M, Jiang L, Hu J, Ye YZ. Clinical charectristic of Mycoplasma pneumoniae-associated ischemic stroke in children. Zhongguo Dang Dai Er Ke Za Zhi 2012;14:823-826.
Tuuminen T, Varjo S, Ingman H, Weber T, Oski J, Viljanan M. Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae Immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays. Clin Diagn Lab Immunol 2000;7:734-738.
TaghizadeS,Honarmand H, Taramsari M, Mirbluk F.Seroprevalence of Mycoplasma pneumonia antibodies in patient with acute myocardial infarction. Biological Journal of Lahigan University 2008; 3:1-9. (In Persian)
Reza Golmohammadi, Ramezan Ali Ataee, Gholam Hossein Alishiri, Reza Mirnejad, Ali Mehrabi Tavana, and Davoude Esmaieli. Design of PCR-based method for detection of a gene-encoding Mycoplasma arthriti- dis mitogen superantigen in synovial fluid of rheuma- toid arthritis patients. Iran J Microbiol 2014; 6: 415–420.
Ataee RA, Golmohammadi R, Alishiri GH, Mirnejad R, Najafi A, Esmaeili D, et al. Simultaneous detection of Mycoplasma pneumoniae, Mycoplasma hominis and Mycoplasma arthritidis in synovial fluid of patients with rheumatoid arthritis by multiplex PCR. Arch Iran Med 2015; 18: 345 – 350.
Tavo V. Prevalence of Mycoplasma hominis and Ureaplazma urealyticum among women of reproduc- tive age in Albania. Med Arch 2013; 67:25-26.
| Files | ||
| Issue | Vol 8 No 6 (2016) | |
| Section | Articles | |
| Keywords | ||
| Mycoplasma pneumoniae CVA Iran Seroprevalence | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
